The quantitative contributions of pancreatic responsiveness and insulin sensitivity to glucose tolerance were measured using the "minimal modeling technique" in 18 lean and obese subjects (88-206% ideal body wt). The individual contributions of insulin secretion and action were measured by interpreting the dynamics of plasma glucose and insulin during the intravenous glucose tolerance test in terms of two mathematical models. One, the insulin kinetics model, yields parameters of first-phase (phi 1) and second-phase (phi 2) responsivity of the beta-cells to glucose. The other glucose kinetics model yields the insulin sensitivity parameters, SI. Lean and obese subjects were subdivided into good (KG greater than 1.5) and lower (KG less than 1.5) glucose tolerance groups. The etiology of lower glucose tolerance was entirely different in lean and obese subjects. Lean, lower tolerance was related to pancreatic insufficiency (phi 2 77% lower than in good tolerance controls [P less than 0.03]), but insulin sensitivity was normal (P greater than 0.5). In contrast, obese lower tolerance was entirely due to insulin resistance (SI diminished 60% [P less than 0.01]); pancreatic responsiveness was not different from lean, good tolerance controls (phi 1: P greater than 0.06; phi 2: P greater than 0.40). Subjects (regardless of weight) could be segregated into good and lower tolerance by the product of second-phase beta-cell responsivity and insulin sensitivity (phi […] product of second-phase ,-cell responsivity and insulin sensitivity (b2-SI). Thus, these two factors were primarily responsible for overall determination of glucose tolerance.
INTRODUCTION
The ability to dispose of carbohydrate depends on the responsiveness of the pancreatic p-cells to glucose and the sensitivity of the glucose utilizing tissues to the secreted insulin. Insulin resistance is an important factor particularly in the etiology of type II, nonketosis prone diabetes (1) (2) (3) (4) (5) . The primacy of insulin resistance in this state remains controversial, however, and most investigators agree that at least a relative impairment in pancreatic secretory capacity is important in noninsulin-dependent diabetic states (6) (7) (8) .
Understanding the etiology of the various forms of impaired glucose tolerance requires techniques for measuring both pancreatic responsiveness and insulin sensitivity, and a means to evaluate their relative contributions to overall glucose tolerance. The major difficulty in making independent measures of these two factors is the glucose insulin feedback rela-tionship, which tends to complicate glucose/insulin dynamics and obscure the causality of impaired tolerance (9) . During the past decade, several laboratories have approached this problem by breaking the feedback relationship, either by pharmacological suppression of pancreatic insulin secretion (10) or by external feedback control (glucose clamp) to circumvent the effect of plasma insulin to change plasma glucose (11) . These methods for measuring insulin sensitivity have contributed to understanding the etiology of intolerance, but they require extensive experimental manipulation, entail some risk to the patient, and have been used only in a few clinical research centers.
We have developed a new approach to quantify both pancreatic responsiveness and insulin sensitivity in the intact organism. This method, the "minimal model" technique, uses computer modeling to analyze the plasma glucose and insulin dynamics during an intravenous glucose tolerance test (IVGTT) .' A mathematical model of pancreatic insulin release and distribution is used to obtain characteristic parameters of insulin secretory responsiveness to glucose (both first phase [0,] and second phase [4k] ) by predicting the time-course of plasma insulin, when the plasma glucose time-course is supplied (12) . Conversely, an index of insulin sensitivity (SI) is measured from a second model that predicts glucose kinetics, when the insulin time-course is supplied (13) . The three characteristic parameters (4k, 02, and SI) represent an integrated metabolic portrait of a single individual. Because it is not necessary to interrupt the glucose-insulin feedback relationship, the experimental manipulations can be performed in a routine clinical setting with minimal patient risk.
In this report we present the first application of the minimal model approach to analysis of glucose tolerance in humans. The purpose of the study was to determine the specific contributions of pancreatic responsiveness and insulin sensitivity to normal and low glucose tolerance in lean and obese subjects. METHODS Subjects. IVGTT Analysis of data. The theoretical basis underlying estimation of the characteristic parameters from IVGTT results has been published in detail (12) (13) (14) , and will only be summarized here. KG values, calculated for purposes ofcomparison with our parameters, were calculated as the least-squares slope of the ln (glucose concentration) vs. time relationship between 10 and 42 min after glucose injection.
General approach: partition and minimal modeling. The system regulating the glucose concentration is envisioned as being partitioned into two parts: (a) the glucose-dependent segment that determines the plasma insulin (the pancreas and insulin-degrading tissues) and (b) the insulin-dependent segment which determines the plasma glucose (glucose producing and utilizing tissues). We have previously evolved specific "minimal" mathematical models for each of the two parts. The two minimal models selected have been shown to be the simplest physiologically based representations that can respectively account (a) for the observed glucose kinetics when the plasma insulin values are supplied and (b) for the observed insulin kinetics when the plasma glucose values are supplied. Using the two independent minimal models to describe the dynamic glucose and insulin responses during IVGTT, characteristic parameters ofinsulin sensitivity and pancreatic responsivity are generated.
Parameter ofinsulin sensitivity, S,. The minimal model of glucose disappearance is diagrammed in Fig. la . The coefficients ofthe minimal model (c.f., reference 13) are estimated for a single individual from the IVGTT data by allowing the model to predict the observed fall in plasma glucose when the (measured) plasma insulin is supplied. In accounting for the glucose kinetics by considering plasma insulin as input and plasma glucose as output it is not necessary to formulate any assumptions as to the mechanisms by which pancreatic insulin secretion is controlled ("partition analysis" [14] ). S, can be calculated (13) Explicit definitions of X and the parameters in terms of fractional turnover constants are found in reference (13) . (B) Model of insulin kinetics used to calculate pancreatic responsivity parameters 41 and O2 (12) . G(t) is supplied to this model, which predicts I(t). First-phase insulin release is represented as a bolus of insulin entering the plasma compartment at the time of the glucose injection (30) . Sensitivity of the first-phase release to glucose is 1 = Io/nAG, where lo is the early peak plasma insulin concentration, n is the time constant for insulin disappearance (min-') and AG is the maximum change in the glucose concentration due to the glucose injection. Second-phase insulin secretion is described by
The rate of increase of second-phase secretion is proportional (by fy) to the degree by which glucose exceeds a threshold level (h). The factor O2 represents the sensitivity of the rate of rise of the second phase to glucose, and is defined as second-phase pancreatic responsivity.
Parameters of pancreatic responsiveness to glucose, X, and 0,. Insulin secretory parameters are calculated for a given individual from the IVGTT by using our minimal model of insulin secretion and disapparance (Fig. lb) . The model assumes that the early peak in insulin secretion represents an "injection" of insulin into plasma by the pancreas in direct proportion to the rise in glucose. First-phase responsivity (0,) is the amount of insulin (per unit volume) that can be accounted for by this assumed injection, per unit change in plasma glucose. It is assumed in the model that the rate of rise of second-phase insulin secretion is proportional to the plasma glucose; the second-phase responsivity (42) is the proportionality factor between glucose and the rate ofrise (15, 16) .
Methods of parameter estimation. Parameter estimation was perfonned on a digital computer (IBM 370/168, IBM Corp., White Plains, N. Y.) using a nonlinear least squares technique (17) , and accuracy of the parameter estimates was evaluated using the covariance matrix (18) . Analysis of the relation between estimated parameters within patient groups was performed using Student's t test and regression analysis (19) .
RESULTS
Analysis of IVGTT. Characteristics of the 18 subjects are listed in Table I . Basal glucose values were all < 115 mg/dl. There were significant positive correlations between the IBW and both basal glucose (r = 0.59, P < 0.01) and insulin (r = 0.62, P < 0.01).
IVGTT results are summarized in Table II . Because the lean control subjects tended to be taller than the obese patients, the dose of glucose based upon IBW was 14% greater in the lean subjects. This difference in dose was reflected in an incremental change in plasma glucose concentration (A glucose) of 194+11 mg/dl in the lean subjects; 21% greater than the increment in the obese (A glucose = 153+14 mg/dl; P < 0.025). Despite the lesser increase in plasma glucose concentration in the obese, they manifested a 2.8-fold greater integrated insulin response. No significant overall difference in KG values was observed in obese vs. lean subjects (P > 0.09), although the obese KG tended to be lower. Thus, to some extent at least, it was apparent that obese patients were able to compensate for overall insulin resistance by means of pancreatic hyperresponsivity. The frequency distribution of KG for all subjects is shown in Fig. 2 . Although the distribution was not absolutely bimodal, there was separation of individuals at KG = 1.5. For purposes of analysis, we chose KG> 1.5 as "good tolerance" and KG < 1.5 as "low tolerance." Five lean and three obese subjects had good tolerance; seven obese and three lean individuals segregated as "low tolerance." Fig. 3 shows the glucose and insulin during the IVGTT of four patient groups, segregated on the bases of body weight and glucose tolerance: group I (lean, good tolerance); group II (lean, low tolerance); group III (obese, good tolerance) and group IV (obese, low tolerance). In all groups, glucose injection provoked rapid insulin secretory responses characterized by an early peak at 4 min, followed by a prolonged secondary phase; however, qualitative differences in the shapes and magnitudes were observed (Fig. 3) . For example, only modest first and second phases were evident in the responses of group II, in contrast to the other three groups. Also, the second phases were prolonged in groups II and IV, when compared with their respective good-tolerance counterparts. The goal of our analytic approach is to account for the variations in glucose tolerance in terms of the specific contributions of pancreatic responsiveness and insulin sensitivity. To do this, we used the two minimal models to describe the IVGTT data of each patient. Fig. 4 shows for two patients the ability of the glucose disappearance model (Fig. la) to describe glucose kinetics, given insulin, and the ability of the insulin kinetics model (Fig. lb) to describe insulin kinetics, given glucose. The specific model coefficients obtained from modeling the dynamics of all patients (separated into groups) are given in Table III. Characteristic metabolic parameters. The coefficients of the two models listed in Table III were reduced to three characteristic metabolic parameters: 0, 0,, and S, (Table IV) . Low tolerance in lean subjects was associated with insufficient pancreatic responsiveness. Although SI was the same in the lean good tolerant and lean low tolerant subjects (group I; SI = 4.0+1.0; group II; SI = 5.1+ 1.3 min-4/,uU per ml; P > 0.5), the low tolerance of lean patients (group II) was associated with a 77% lower second-phase responsivity, compared with the lean good tolerant group I (P < 0.03). There was also a tendency for first-phase responsivity to be lower in the second group but the difference in (1 was not significant (P < 0.08) because of wide variation in (1l.
In contrast to the lean individuals, low glucose tolerance in the obese patients was related to insulin resistance rather than diminished pancreatic responsiveness. Insulin sensitivity was 60% diminished in group IV obese low tolerance patients (compared with lean, good tolerance group I controls; [P < 0.01]), whereas in the group IV patients second-phase responsiveness was not different from group I (31+6 compared with 27+7; P > 0.4). As in the lean patients, there was wide variation in (1 in the group IV patients (range of Xl: 1.0 to 18.2). However, even in those group IV patients for whom 0, was increased (subjects 13 and 15, for example [ Table IV ]), the increased first phase responsivity was not sufficient to overcome the intolerance occasioned by normal 1)2 coupled with a severely diminished S, typical of the obese, low tolerance individuals.
Significance of k2 SI in determining tolerance.
Since impaired tolerance can be associated with either diminished second-phase responsivity or SI, we examined the hypothesis that the product O2 Si ("disposition factor") may be a convenient means for segregating individuals of varying tolerance, regardless of weight. The value of this product was 160+26 for all good tolerance subjects and 40+7 (P < 0.001) for the low tolerance subjects (Table IV) . Fig. 5 (top) indicates thatO2 (SI for 9 of the 10 low tolerance individuals is below 75, and that the product exceeds 75 for 7 of the 8 good tolerance subjects. Also shown in Fig. 5 is the relationship between Si and 12 for all subjects. The hyperbola representing 02 SI = 75 separates most good tolerant (upper right) from low tolerant (lower left) subjects. Thus, the position of a subject on this plot (above or below the "75" curve) determines not only whether the subject is tolerant, but also the relative contribution ofpancreatic responsiveness (02) or SI to the degree of tolerance that the individual exhibits.
Influence of first-phase responsivity on glucose tolerance. The ability to segregate on the basis of tolerance, in terms of the O2* Sl product alone suggests that these two factors are primarily responsible for glucose tolerance in a given individual. Due to the wide variation of (l within groups, it was not possible to obtain clear segregation using 11-SI (not shown). Nonetheless, first-phase insulin responsivity appears to play a role in the determination of tolerance within groups whose overall tolerance is determined by O2 Sl. Fig. 6 shows the relation between K6, and X1 in the four groups. KG was highly correlated with 40, in the obese, low tolerance subjects (group IV; r = 0.91, P < 0.001). Presumably due to the relative insulin resistance of these subjects ( (20) ; and insulin-independent glucose uptake (21) . We have referred to the sum of these factors as "glucose effectiveness" (13) . It is of interest to consider whether alterations in glucose effectiveness contribute to the glucose intolerance of the obese subjects.
In the glucose kinetics model (Fig. lb) (22, 23) . Fig. 7 demonstrates that for those patients for whom SI is <3.0 min-1/,uU per ml, basal insulin is correlated with SI (r = 0.65, P < .03). However, over the range of insulin sensitivities from 3.0-10.0 min-' ,U per ml the correlation was not observed (r = 0.08). t Parameter n is the fractional clearance of insulin (min-'); the value ofn was assumed for those subjects for whom there was no significant first-phase insulin secretion. The parameter was assumed equal to the average n for the patients with a first phase with matched body weights (lean or obese). 5 Number in parentheses is the average percent fractional SD of the parameter (CV x 100). DISCUSSION and glucose dynamics during an IVGTT to estimate the coefficients oftwo mathematical models: one ofglucose In the present study, we have demonstrated the feasi-kinetics and a second of insulin kinetics. The utility of bility of a new approach to relating pancreatic respon-our approach is demonstrated by its ability to differensiveness and insulin sensitivity to the glucose tolerance tiate the causality of observed low glucose tolerance of human subjects. These metabolic features, expressed between lean and obese subjects. In the lean intolerant in terms ofthe three metabolic parameters 01, 42, and SI individuals, Sl was identical with that of lean tolerants; can usually be measured by using the precise insulin intolerance was related to pancreatic insufficiency (2) 250 (1) 337 (2) 329 (2) i
296 (1) 248 (2) 271 (2) (Table III) . Slopes of the two lines are significantly different (P < 0.01).
simulate a wide variety of glucose dynamic patterns (13) . It is doubtful the 60% diminution in insulin sensitivity in the obese can be an artifact of a 26% difference in glucose increment. Nonetheless, we believe that a more complete study of the range of doses over which the model is applicable would be worthwhile. is independent of acute changes in insulin it may be related to the influence of basal insulin concentration on the levels of those enzymes that are dependent upon a constant insulin environment for their activities, such as glucokinase and glycogen synthase in the liver (29, 30) and glucose transport units in tissues for which glucose transport is insulin dependent (31) . Thus, the diminished glucose effectiveness may be related to insulin resistance in that it could be a secondary manifestation of the resistance of tissues to the "permissive" rather than acute effects of the hormone.
The present results provide the opportunity to examine whether basal insulin levels represent a good measure of insulin sensitivity (22, 23) . A good negative correlation between basal insulin and Si was observed under conditions of frank insulin resistance (Si < 3.0); however, over the large range of S, in normal, tolerant subjects (3.0 < SI < 10.0) a significant correlation between basal insulin and measured resistance was not observed. (That sensitivity can vary over such a large range in normal individuals was originally reported by Sherwin and his colleagues [32] , and we have a similar experience in normal dogs [13] ). It is not surprising, however, that in normal individuals, basal insulin is not a simple function of Si, but also depends on factors which may themselves change with insulin resistance. Insulin levels are also determined by basal pancreatic insulin secretion, insulin clearance, and neural mechanisms (33) . When frank insulin resistance is manifest, it is reasonable that the resistance effect can overwhelm other mechanisms that control basal insulin, and hyperinsulinemia in proportion to the resistance is observed. However, when S, is in the normal range, it is only one of several possibly equipotent factors which determine basal insulin, and the clear correlation between SI and basal insulin disappears.
Therefore, although there may be a correlation between basal insulin and Sl, particularly in the insulin resistant state, the former apparently cannot be viewed as an accurate measure of the latter under all conditions.
The present studies demonstrate that the minimal model approach may be applicable to studying the etiology of altered carbohydrate metabolism in man. In addition to comparative validation with other techniques, it will be useful to explore whether the IVGTT is the optimal perturbation to be used to estimate metabolic parameters. Present studies have been limited to evaluation of IVGTT results. It remains to be proven whether the model and its parameters will apply and can be obtained from other doses and other stimulus patterns. Possibly future studies will yield a better temporal pattern of glucose and/or insulin administration that will lead to easier estimation of metabolic parameters. In any event, complete validation of the model and optimal input patterns will be required before the approach can be proposed as a clinical tool.
